Johnson & Johnson $JNJ Stock: Voya Investment Management LLC Trims Stake

Johnson & Johnson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Voya Investment Management cut its Johnson & Johnson stake by 9.1% in the third quarter, selling 295,886 shares. It still held about 2.96 million shares, valued at roughly $783 million.
  • Analyst views were mixed, but the consensus rating remained “Moderate Buy”, with an average price target of $275.92. One analyst rated J&J Strong Buy, 17 rated it Buy, and eight rated it Hold.
  • J&J reported quarterly revenue of $25.4 billion, up 5.9% year over year, and EPS of $2.59, topping estimates. It declared a quarterly dividend of $1.34 per share, equivalent to a 1.9% yield.
  • Five stocks to consider instead of Johnson & Johnson.

Voya Investment Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 9.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,959,681 shares of the company's stock after selling 295,886 shares during the quarter. Johnson & Johnson accounts for approximately 0.7% of Voya Investment Management LLC's holdings, making the stock its 26th biggest position. Voya Investment Management LLC owned approximately 0.12% of Johnson & Johnson worth $783,225,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock worth $5,736,851,000 after buying an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Johnson & Johnson by 8.5% in the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company's stock worth $3,977,506,000 after buying an additional 1,225,676 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Johnson & Johnson by 11.5% in the third quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company's stock worth $3,927,981,000 after acquiring an additional 1,530,070 shares during the period. Amundi increased its position in Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company's stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company's stock valued at $1,924,323,000 after acquiring an additional 148,497 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Wall Street Zen downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Johnson Rice downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday, October 21st. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a research report on Friday, October 16th. Evercore set a $300.00 price target on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, Citigroup increased their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a "buy" rating in a research note on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $275.92.

View Our Latest Stock Analysis on JNJ

Insider Activity

In other news, EVP Elizabeth Forminard sold 13,072 shares of the firm's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is owned by company insiders.

More Johnson & Johnson News

Investors following JNJ have been watching these news items:

  • Positive Sentiment: J&J’s planned acquisition of Ollin Biosciences adds a Phase 3 candidate for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. The deal includes $2.2 billion upfront and up to about $1.1 billion in milestone payments; Blackstone is expected to provide $750 million toward development. UBS sees the asset as a potential growth driver beyond 2030. J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition UBS on Ollin as a Growth Driver
  • Neutral Sentiment: The Ollin acquisition strengthens J&J’s ophthalmology portfolio, but its late-stage drug would enter a competitive market and still faces clinical and commercial execution risks. J&J Bets $2.2B on Ollin’s Vision Loss Drug
  • Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar mesothelioma verdict against J&J related to its talc baby powder, adding to ongoing litigation concerns. Separately, Pomerantz LLP said it is investigating claims on behalf of J&J investors; an investigation is not a finding of wrongdoing, but may add uncertainty. Louisiana Appeals Court Upholds Damages in Mesothelioma Case Pomerantz Investor Alert

Johnson & Johnson Trading Down 1.5%

Shares of JNJ stock opened at $278.42 on Wednesday. Johnson & Johnson has a 1 year low of $198.53 and a 1 year high of $290.25. The firm has a fifty day moving average price of $267.31 and a 200-day moving average price of $250.38. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The company has a market cap of $670.23 billion, a price-to-earnings ratio of 42.18, a PEG ratio of 2.79 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period in the prior year, the business posted $2.80 EPS. Johnson & Johnson's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines